GlassScriptPhysician profile
Karen E Callahan
NPI 1154371508
$5,005.32
in general payments reported to CMS, 2019-2025
25 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $901 · 2021: $1,031 · 2022: $1,121 · 2023: $629 · 2024: $453 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $995.88 | 2019-2022 | |
| Abbvie INC. | $942.24 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $396.40 | 2020-2024 | Caplyta |
| Lundbeck LLC | $354.39 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $350.30 | 2020-2023 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $318.36 | 2019-2024 | Spravato |
| Alkermes, INC. | $306.77 | 2020-2023 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $233.83 | 2019-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $173.30 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $159.48 | 2020-2022 | |
| Axsome Therapeutics, INC. | $114.86 | 2022-2023 | Auvelity |
| Neurocrine Biosciences, INC. | $76.90 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $76.67 | 2019-2024 | |
| Allergan, INC. | $73.32 | 2019-2020 | |
| Corium, LLC | $67.11 | 2022-2023 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $66.45 | 2022-2024 | Uzedy |
| Almatica Pharma LLC | $60.70 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Indivior INC. | $60.56 | 2020-2021 | |
| Neos Therapeutics, LP | $56.85 | 2021-2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $50.91 | 2023-2024 | Xelstrym, Secuado |
| Alfasigma USA, INC. | $16.27 | 2022 | |
| Brainsway USA INC | $15.10 | 2025 | Deep Tms System |
| Eisai INC. | $14.23 | 2020 | |
| Merck Sharp & Dohme LLC | $12.30 | 2021 | |
| Adlon Therapeutics L.P. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.